Geniculate Ganglionitis Drugs Market

Geniculate Ganglionitis Drugs Market Segmentation by Treatment (Drugs, and Surgery); by Drug Type (Anticonvulsant, Anti-inflammatory Drugs, Antiviral Drugs, Tricyclics, Pregabalin, and Others); and by Distribution Channel (Hospital, Pharmacies, Specialty Clinics, and Others) – Global Demand Analysis & Opportunity Outlook 2030

Buy Now
Report ID: 3503 | Published On: Feb 08, 2023

Preview Analysis

Request Insights
Despite Inflation & Recession News, Businesses Across the Globe Expected to Do Better in 2023

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.


In The News


Global Geniculate Ganglionitis Drugs Market Highlights Over 2022 – 2030

The global geniculate ganglionitis drugs market is estimated to grow at CAGR of ~5% over the forecast period, i.e., 2022 – 2030. Geniculate ganglionitis, also known as, Ramsay Hunt syndrome, or Hunt's neuralgia, is a neurological disorder caused by infection with the same virus which causes chickenpox. In this syndrome, the virus infects the facial nerve connected to the ear, which is why the syndrome is characterized by chronic pain in middle and inner ear. The growth of the market can be attributed to the rising cases of chickenpox and shingles, as this is the most common cause of geniculate ganglionitis. Before the mass vaccine drives for chickenpox were initiated, over 100 deaths and more than 4 million cases of chickenpox were reported every year. After the vaccine drives, since 1996, this has reduced significantly. As of 2019, less than 350,000 cases of chickenpox were reported worldwide. Moreover, the developing public healthcare infrastructure and high government expenditure for the development of new drugs is anticipated to significantly fuel the growth of the market.

Global Geniculate Ganglionitis Drugs Market

Get more information on this reportDownload Sample PDF

The global geniculate ganglionitis drugs market is segmented by drug type into anticonvulsant, anti-inflammatory drugs, antiviral drugs, tricyclics, pregabalin and others, out of which, the antiviral drugs segment is anticipated to hold notable share over the forecast period as antiviral drugs can suppress the infection and instantly reduce the damage to the nerve. However, there is no specific treatment for geniculate ganglionitis, and a combination of drugs is used to relieve the symptoms. 


Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.


Global Geniculate Ganglionitis Drugs Market Regional Synopsis

On the basis of geographical analysis, the global geniculate ganglionitis drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to witness substantial growth over the forecast period on the back of higher cases of chickenpox and other viral infections due to lack of health awareness and poor healthcare system in developing nations, such as, India, Vietnam, Bangladesh, and Indonesia. Similarly, the market in Latin America is estimated to provide significant opportunities for the market to grow by the end of 2030, owing to absence of proper vaccine drives to protect for VZV virus, and lack of proper treatment facilities in the region.

The market in the North America region is anticipated to gain the largest market share throughout the forecast period on account of presence of major pharmaceutical companies manufacturing drugs, and increasing research activities for the developing new drugs.

Geniculate Ganglionitis Drugs Market

Get more information on this reportDownload Sample PDF

The global geniculate ganglionitis drugs market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis


Global Geniculate Ganglionitis Drugs Market
Get more information on this report: Request Sample PDF

Market Segmentation

Our in-depth analysis of the global geniculate ganglionitis drugs market includes the following segments:

By Treatment

  • Drugs
  • Surgery

By Drug Class

  • Anticonvulsant
  • Anti-inflammatory Drugs
  • Antiviral Drugs
  • Tricyclics
  • Pregabalin
  • Others

By Distribution Channel

  • Hospital
  • Pharmacies
  • Specialty Clinics
  • Others

Growth Drivers

  • Increasing Infection of Varicella-Zoster Virus (VZV)
  • Rising R&D for Drugs and Treatment Methods

Challenges

  • Lack of Health Awareness in Low-Income Countries


Healthcare Expenditure
Get more information on this report: Request Sample PDF

Top Featured Companies Dominating the Market

    • Baxter International, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Siemens Healthcare GmbH
    • Pfizer Inc.
    • Novartis AG
    • Sanofi-aventis Groupe
    • Abbott Laboratories
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Daiichi Sankyo Company, Limited
    • Janssen Pharmaceuticals, Inc.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the geniculate ganglionitis drugs market?

Ans: The growing cases of chickenpox and severe symptoms of the disorder to boost the market growth.

2) What would be the CAGR of geniculate ganglionitis drugs market over the forecast period?

Ans: The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2022 – 2030.

3) What are the challenges affecting the geniculate ganglionitis drugs market growth?

Ans: Lack of health awareness in low-income countries is estimated to hamper the market growth.

4) Which region will provide more business opportunities for growth of geniculate ganglionitis drugs market in future?

Ans: The market in the Asia Pacific is estimated to witness growth with highest CAGR over the forecast period, owing to the increasing infection of virus, and developing healthcare system.

5) Who are the major players dominating the geniculate ganglionitis drugs market?

Ans: The major players in the market are Pfizer Inc., Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, and Janssen Pharmaceuticals, Inc.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the geniculate ganglionitis drugs market?

Ans: The market is segmented by treatment, drug type, distribution channel, and by region.

8) Which segment captures the largest market size in treatment segment in the geniculate ganglionitis drugs market?

Ans: The drugs segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Submit RFP    Buy Now Download Research Report Sample